Gandeeva Therapeutics

Gandeeva Therapeutics is a precision biotechnology company based in Burnaby, Canada, founded in 2021. The company focuses on drug discovery by integrating artificial intelligence, machine learning, and cryogenic electron microscopy (cryo-EM). Its mission is to develop therapies that target protein interactions at the atomic level, primarily in oncology and other complex diseases such as cancer and infectious diseases.

Gandeeva's proprietary platform automates cryo-EM imaging to characterize protein-drug interactions, facilitating the design of precision medicines, including small molecules and engineered antibodies. The company has raised $40 million in Series A funding to advance its AI-enabled platform. Its pipeline includes several preclinical programs, such as chemical drugs and small molecule drugs, aimed at modulating protein interactions for therapeutic effects. Gandeeva also explores licensing technologies and collaboration opportunities in drug discovery and development.